Inventor · disambiguated record
James Gail Christensen
Also filed as: CHRISTENSEN JAMES G · CHRISTENSEN JAMES GAIL
21 granted patents·23 pending applications·142 citations·filing 2005–2025
94Inventor score
Top patents by PatentIndex Score
44 records- 0197US10689377B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Jun 23, 2020·16 cites·57 claims
- 0296US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0396US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0496US10125134B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Nov 13, 2018·43 cites·9 claims
- 0593US10633381B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·8 cites·7 claims
- 0692US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0792US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 0891US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 0991US9809541B2LSD1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2016·Granted Nov 7, 2017·11 cites·62 claims
- 1089US11890285B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·4 cites·43 claims
- 1186US7825137B2Method of treating abnormal cell growthPFIZER·Filed 2006·Granted Nov 2, 2010·24 cites·7 claims
- 1284US12208099B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Granted Jan 28, 2025·3 cites·9 claims
- 1382US11548888B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jan 10, 2023·1 cites·9 claims
- 1482US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1582US2024101553A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1680US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 1778US2023373999A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1877US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1974US2025073241A1Combination Therapies Using PRMT5 Inhibitors for the Treatment of CancerMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2073US2024423987A1Combination Therapies Using PRMT5 Inhibitors for the Treatment of CancerMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2171US2025108055A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2270US12171765B2Combination therapies using PRMT5 inhibitors for the treatment of cancerMIRATI THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·0 cites·18 claims
- 2370US12128048B2Combination therapies using PRMT5 inhibitors for the treatment of cancerMIRATI THERAPEUTICS INC·Filed 2022·Granted Oct 29, 2024·0 cites·16 claims
- 2468US2024156821A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2566US12336995B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Granted Jun 24, 2025·0 cites·36 claims
- 2666US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 2762US2025262213A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2859US2022040181A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2959US2024228510A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3059US2025213579A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3159US2024398795A1Combination therapies using prmt5 inhibitors for the treatment of cancerMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3258US12485122B2Combination of palbociclib and adagrasib for lung cancerMIRATI THERAPEUTICS INC·Filed 2019·Granted Dec 2, 2025·0 cites·12 claims
- 3357US2025000863A1Combination therapies of kras g12d inhibitors with sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3457US2024408098A1COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENTMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3557US2024408099A1COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORSMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3657US2025249003A1Combinations of kras g12d inhibitors with irinotecan and related methods of treatmentMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3757US2024423984A1Combination therapies of kras g12d inhibitors with shp-2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3853US2023383359A1Methods for treatment of lung cancersMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3953US2023279025A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4051US10233152B2LSD1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·0 cites·23 claims
- 4150US12377101B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·0 cites·11 claims
- 4250US2025177399A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4344US2006035907A1Methods of treating abnormal cell growth using c-MET and m-TOR inhibitorsCHRISTENSEN JAMES G·Filed 2005·Application pending·0 cites
- 4439US2016206608A1Crizotinib for use in the treatment of cancerCHRISTENSEN JAMES GAIL·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James Gail Christensen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →